News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The campaign highlights a straightforward, achievable approach to health, proving that supporting your wellness doesn’t have to be complicated
IntraSight Plus enables confident decision-making and better patient care,” Philips said, emphasizing efficiency, simplicity, and precision
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
The move comes as drug developers face mounting pressure from faster timelines and increasingly complex manufacturing processes
Subscribe To Our Newsletter & Stay Updated
